Scribe Therapeutics Inc.
SCTX
NASDAQ·Healthcare·Biotechnology·Mkt cap $463.9M
$28.67
▼ -6.95%
P/E
—
Mkt Cap
$463.9M
52-Wk Range
$17.31–$39.60
52-Week Range
$17.31 - $39.60
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 91.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
No forward estimates available
Value
Valuation data unavailable
Momentum
Hot
+91.1% over 3m
Quality
Solid
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying SCTX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
SEP 2, 2026
Reported EPS of -$2.62 vs -$3.62 consensus (+27.6% surprise). Revenue of $1.9M vs $3.1M expected (-38.9%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+27.6%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: HC Wainwright · Aug 31, 2026
vs Industry
How SCTX stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.